Upcoming events on MERCK & CO., INC. |
|
02/04/21 | 06:45am | | FY 2020 Earnings Release |
02/04/21 | 08:00am | | FY 2020 Earnings Call |
04/29/21 | | Q1 2021 Earnings Release |
04/29/21 | 08:00am | | Q1 2021 Earnings Call |
|
Past events on MERCK & CO., INC. |
|
01/11/21 | 04:30pm | | JP Morgan Healthcare Conference |
12/14/20 | | Ex-dividend day for |
12/02/20 | 09:40am | | Evercore ISI HealthCONx Conference |
11/09/20 | | ABRCMS Virtual Conference |
|
Upcoming sector events for MERCK & CO., INC. |
|
|
|
Past sector events for MERCK & CO., INC. |
|
|
|
Annual results | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (e) |
Sales M $ |
Released Forecast Spread | 39 498 39 600 -0,26% | 39 807 39 991 -0,46% | 40 122 40 205 -0,21% | 42 294 42 234 0,14% | 46 840 46 818 0,05% | 48 203
|
Operating income (EBITDA) M $ |
Released Forecast Spread | 19 757 15 314 29% | 19 154 19 083 0,37% | 15 131 15 472 -2,2% | 15 781 15 310 3,1% | 19 572 18 761 4,3% | 19 888
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 13 382 13 401 -0,14% | 13 713 13 698 0,11% | 13 551 13 722 -1,2% | 13 926 13 815 0,80% | 15 920 16 276 -2,2% | 17 403
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 5 401 6 210 -13% | 7 499 7 288 2,9% | 6 747 6 720 0,40% | 8 701 8 296 4,9% | 11 464 12 277 -6,6% | 14 782
|
Net income M $ |
Released Forecast Spread | 4 442 4 786 -7,2% | 5 691 5 779 -1,5% | 2 568 5 147 -50% | 6 220 6 462 -3,7% | 9 843 9 957 -1,1% | 12 158
|
EPS $ |
Released Forecast Spread | 1,56 1,64 -4,6% | 2,04 2,03 0,57% | 0,93 1,85 -50% | 2,32 2,44 -5,0% | 3,81 3,83 -0,52% | 4,74
| Announcement Date | 02/03/2016 | 02/02/2017 | 02/02/2018 | 02/01/2019 | 02/05/2020 | |
|
|
Quarterly results | 2018 Q2 | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 (e) | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) |
Sales M $ |
Released Forecast Spread | 10 465 10 304 1,6% | 10 794 10 888 -0,86% | 10 998 10 929 0,63% | 10 816 10 452 3,5% | 11 760 10 943 7,5% | 12 397 11 593 6,9% | 11 868 11 927 -0,49% | 12 057 11 458 5,2% | 10 872 10 657 2,0% | 12 551 12 213 2,8% | 12 656
| 12 829
| 12 589
| 13 210
| 13 036
|
Operating income (EBITDA) M $ |
Released Forecast Spread | 3 861 3 752 2,9% | 4 830 4 170 16% | 4 064 3 762 8,0% | 4 324 3 759 15% | 4 665 4 072 15% | 5 474 4 639 18% | 4 336 4 676 -7,3% | 4 802 4 715 1,8% | 4 707 3 911 20% | 5 744 4 862 18% | 4 611
| 5 512
| 5 502
| 5 618
| 5 291
|
Operating profit (EBIT) M $ |
Released Forecast Spread | 3 367 3 421 -1,6% | 3 769 3 720 1,3% | 3 489 3 371 3,5% | 3 823 3 390 13% | 4 070 3 646 12% | 4 629 3 989 16% | 3 400 3 777 -10,0% | 3 981 4 205 -5,3% | 3 659 3 238 13% | 4 892 4 342 13% | 4 053
| 4 838
| 4 345
| 4 943
| 4 929
|
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 2 086 2 529 -18% |
|
| 3 067 2 984 2,8% |
|
|
|
|
|
|
|
|
|
|
|
Net income M $ |
Released Forecast Spread | 1 707 1 950 -12% | 1 950
| 1 827
|
|
| 1 901 2 546 -25% | 2 357 2 458 -4,1% | 3 219 2 856 13% | 3 002 2 323 29% | 2 941 2 575 14% | 2 773
|
|
|
|
|
EPS $ |
Released Forecast Spread | 0,63 0,72 -13% | 0,73 0,84 -13% | 0,69 0,85 -19% | 1,12 0,88 27% | 1,03 0,99 4,0% | 0,74 0,96 -23% | 0,92 0,94 -1,8% | 1,26 1,12 13% | 1,18 0,91 29% | 1,16 1,02 14% | 1,05
| 1,03
| 0,98
| 0,93
| 1,02
| Announcement Date | 07/27/2018 | 10/25/2018 | 02/01/2019 | 04/30/2019 | 07/30/2019 | 10/29/2019 | 02/05/2020 | 04/28/2020 | 07/31/2020 | 10/27/2020 | | | | | |
|
Financial data source © 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
|
Merck to move COVID-19 treatment into large trials, sees sales recovering this year |
|
MERCK AND COMPANY Leader in oncology, modest valuation |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|